Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents

NCT00518180 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00518180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00518180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
October 31, 2008
Enrollment
1,620 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection, meningococcal meningitis, pertussis, tetanus